Sterility
0
Pipeline Programs
2
Companies
5
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Ferring PharmaceuticalsArgentina - Buenos Aires
4 programshMG-HPN/A1 trial
hMG-HPN/A1 trial
hMG-HPN/A1 trial
hMG-HP/r-FSHN/A1 trial
Active Trials
+1 more trials
M&
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Merck & Co.GnRH-ant protocol
Ferring PharmaceuticalshMG-HP
Ferring PharmaceuticalshMG-HP
Ferring PharmaceuticalshMG-HP/r-FSH
Ferring PharmaceuticalshMG-HP
Clinical Trials (5)
Total enrollment: 1,410 patients across 5 trials
To Investigate the Cumulative Live Birth Rates Using GnRH Antagonist or Agonist Protocol for COS in ART Treatment
Start: Dec 2018Est. completion: Jul 2022888 patients
N/AUnknown
Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation
Start: Nov 2007Est. completion: Jul 2010279 patients
N/ACompleted
Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist
Start: Nov 2006Est. completion: Mar 2009131 patients
N/ACompleted
Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP
Start: Oct 2006Est. completion: Sep 200851 patients
N/ACompleted
Assessment of the Therapeutic Utility of hMG-HP
Start: Oct 2006Est. completion: Sep 200861 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space